174 related articles for article (PubMed ID: 18553126)
1. Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.
Freise KJ; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):285-323. PubMed ID: 18553126
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.
Freise KJ; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):519-47. PubMed ID: 17516153
[TBL] [Abstract][Full Text] [Related]
3. An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.
Veng-Pedersen P; Chapel S; Schmidt RL; Al-Huniti NH; Cook RT; Widness JA
Pharm Res; 2002 Nov; 19(11):1630-5. PubMed ID: 12458668
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.
Al-Huniti NH; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):359-76. PubMed ID: 16284920
[TBL] [Abstract][Full Text] [Related]
5. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep.
Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
J Pharmacol Exp Ther; 2000 Oct; 295(1):346-51. PubMed ID: 10992000
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
[TBL] [Abstract][Full Text] [Related]
7. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.
Krzyzanski W; Perez-Ruixo JJ
Pharm Res; 2007 Apr; 24(4):758-72. PubMed ID: 17318417
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.
Krzyzanski W; Woo S; Jusko WJ
J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):125-66. PubMed ID: 16565883
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response.
Freise KJ; Schmidt RL; Widness JA; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):527-52. PubMed ID: 18937059
[TBL] [Abstract][Full Text] [Related]
10. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.
Krzyzanski W; Perez-Ruixo JJ; Vermeulen A
J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):349-77. PubMed ID: 18551354
[TBL] [Abstract][Full Text] [Related]
11. A 'bottom-up' approach for endo-PK/PD analysis.
Neelakantan S; Widness JA; Schmidt RL; Veng-Pedersen P
Biopharm Drug Dispos; 2006 Oct; 27(7):313-27. PubMed ID: 16892181
[TBL] [Abstract][Full Text] [Related]
12. Models for the red blood cell lifespan.
Shrestha RP; Horowitz J; Hollot CV; Germain MJ; Widness JA; Mock DM; Veng-Pedersen P; Chait Y
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):259-74. PubMed ID: 27039311
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.
Pérez-Ruixo JJ; Krzyzanski W; Hing J
Clin Pharmacokinet; 2008; 47(6):399-415. PubMed ID: 18479174
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.
Freise KJ; Widness JA; Veng-Pedersen P
J Pharmacol Exp Ther; 2010 Jan; 332(1):229-37. PubMed ID: 19808699
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis.
de Haan G; Dontje B; Engel C; Loeffler M; Nijhof W
Br J Haematol; 1995 Aug; 90(4):783-90. PubMed ID: 7545423
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.
Saleh MI; Widness JA; Veng-Pedersen P
Biopharm Drug Dispos; 2011 Apr; 32(3):131-9. PubMed ID: 21456051
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.
Saleh MI; Nalbant D; Widness JA; Veng-Pedersen P
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(9):R772-81. PubMed ID: 23485870
[TBL] [Abstract][Full Text] [Related]
18. The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats.
Wiczling P; Krzyzanski W; Zychlińska N; Lewandowski K; Kaliszan R
Biopharm Drug Dispos; 2014 Sep; 35(6):330-40. PubMed ID: 24888906
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia.
Al-Huniti NH; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacol Exp Ther; 2004 Jul; 310(1):202-8. PubMed ID: 14988424
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.
Pérez-Ruixo JJ; Krzyzanski W; Bouman-Thio E; Miller B; Jang H; Bai SA; Zhou H; Yohrling J; Cohen A; Burggraaf J; Franson K; Davis HM
Clin Pharmacokinet; 2009; 48(9):601-13. PubMed ID: 19725594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
